Malaria Vaccines Market Size Worth USD 1,612.30 Million by 2034 | CAGR: 12.70%
The global malaria vaccines market size is expected to reach USD 1,612.30 million by 2034, according to a new study by Polaris Market Research. The report “Malaria Vaccines Market Size, Share, Trends, Industry Analysis Report: By Vaccine Type, Administration Route (Subcutaneous and Intramuscular), Target Population, Immunization Schedule, Development Stage, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Malaria is a serious, life-threatening disease caused by Plasmodium parasite, which is transmitted from human to human by the bite of infected mosquitoes. This mosquito-borne illness causes severe disease in kids and adults. Pregnant women and children are particularly vulnerable to the fever caused by malaria. Various precautions to control the disease include the use of insect nets and spraying of pesticides. However, current research studies have shown that insects are immune to pesticides, pesticides have harmful effects on human beings, and malaria fever is becoming immune to medications. In response to these challenges, researchers and pharmaceutical companies have been working on the development of malaria vaccines as an alternative method of prevention.
Several factors, such as the rising incidence of malaria worldwide and the introduction of low-cost malaria vaccines by pharma companies globally, are driving the malaria vaccines market growth. Rising awareness about the disease’s consequences and ongoing research and development (R&D) initiatives are further supporting the market development.
Growing efforts by government and private organizations to address the issues of weak supply chains and distribution networks in some malaria-endemic developing countries are expected to boost the adoption of malaria vaccines. Rising inoculation programs and emphasis on the development of innovative vaccine technologies are expected to provide several malaria vaccines market opportunities in the coming years.
Key Highlights of Malaria Vaccines Market Report
- North America accounted for the largest market share of 34.0% in 2025. The regional market dominance is driven by the strong presence of major pharmaceutical companies with major investments in malaria vaccine development programs.
- The Middle East & Africa is projected to witness a significant CAGR of 18.83%. The regional market growth is driven by increased collaborations for developing cost-effective malaria vaccines.
- The RTS,S/AS01 segment accounted for the largest market share of 58.0% in 2025. The segment’s leading position is attributed to extensive clinical research and trials demonstrating its efficacy.
- The intramuscular segment dominated with a 94.0% market share in 2025. This is primarily because it’s the most widely used route for malaria vaccines.
- The children under 5 years segment is projected to witness the fastest growth at a 11.63% CAGR. This is because children under 5 are the most vulnerable demographic and account for a vast majority of the global malaria deaths.
- Instituto Butantan, Merck, PATH, GSK, Vaxart, Biovac, Pfizer, Inovio Pharmaceuticals, Bharat Biotech, University of Oxford, Intellia Therapeutics, Johnson & Johnson, Sanaria, and Takeda Pharmaceutical Company are a few of the key players in the market.
Request a free sample copy or read the full market insights : malaria vaccines market Report
Polaris Market Research has segmented the malaria vaccines market research report on the basis of vaccine type, administration route, target population, immunization schedule, development stage, and region:
By Vaccine Type Outlook (Revenue – USD Million, 2021–2034)
- PfSPZ
- RTS,S/AS01
- R21/Matrix-M
By Administration Route Outlook (Revenue – USD Million, 2021–2034)
- Subcutaneous
- Intramuscular
By Target Population Outlook (Revenue – USD Million, 2021–2034)
- Travelers to Endemic Areas
- Pregnant Women
- Children under 5 Years
By Immunization Schedule Outlook (Revenue – USD Million, 2021–2034)
- Single Dose
- Multi-Dose
- Booster Doses
By Development Stage Outlook (Revenue – USD Million, 2021–2034)
- Preclinical
- Clinical Trials
By Regional Outlook (Revenue – USD Million, 2021–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Malaria Vaccines Market Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 551.9 million |
| Market Size Value in 2026 | USD 619.7 million |
| Revenue Forecast by 2034 | USD 1,612.30 million |
| CAGR | 12.7% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD million and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
| For Specific Research Requirements |
Source: Polaris Market Research Analysis
